17 June 2026

36 days to PCAC. Roster unchanged: 3 voting members of 12 authorized, 30 weeks without appointment. Oral presentation deadline June 30 (13 days). 503B exclusion comment period closes June 29 (12 days). Historian: 30-week vacancy streak is the longest in Ra's tracking; FDA has filled other advisory committees (CDC ACIP) during this period, making PCAC-specific inaction an increasingly deliberate absence signal. Skeptic: counter-narrative (Kennedy batch-fills) requires action in a domain with zero demonstrated interest for 7+ months. Bayesian: no new evidence, posterior holds. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30 oral deadline — 13 days.

Same vacancy dynamics. Binary-outcome structural concern: 3-member panel favors all-pass or all-defer over moderate 2-of-4. PBS News frames review as "unproven peptides favored by RFK Jr. and MAHA supporters" — if mainstream media locks onto a "political interference in science" frame before July 23, it creates political cover for panel members to defer rather than appear to cave. Not probability-moving yet. Same June 30 checkpoint.

Month 18 post-facility-acquisition at lower bound of 18–24mo base rate. OneTwenty 5+ weeks live, zero FDA enforcement, past 30-day forbearance threshold. FierceHealthcare: Hims expanded into diagnostics and Canada, confirming platform expansion thesis. GuruFocus: Hims stock surged on PCAC news — market-expectation pressure on management to deliver peptide announcement. No launch announcement. Next catalysts: PCAC July 23, then Q2 earnings August.

No new adverse events. LegitScript — the compliance platform used by Google, Facebook, and payment processors — flagged peptides in supplements as an "emerging risk." LegitScript classifications cascade to ad restrictions and payment processing scrutiny; if Google restricts peptide advertising, gray-market vendors migrate to harder-to-monitor channels, accelerating unsafe sourcing. PBS "unproven peptides" framing adds to institutional scaffold for safety narratives. DOJ enforcement infrastructure intact. 286 days to resolution.

T-14 to July 1 launch. Third-party content ecosystem building: Medicare.tools published a Bridge eligibility guide, joining CMS, NCOA, AMCP, Medicare Rights Center, and Obesity Action Coalition in the awareness infrastructure. No enrollment data until post-launch. Next reassessment: early July.

No peptide DTC affiliate programs in Katalys table. First-party: Katalys clicks 315 (+105% WoW), 1 SkinnyRx conversion ($500). GSC impressions 1,028 (-62%), clicks 18 (-47%), CTR improved 1.75%. Thirteenth consecutive Google decline week. But Katalys click doubling confirms non-Google traffic channels compensating. Foundayo Week 7 ~11,700 Rx (Jefferies) vs oral Wegovy >134,000/week — branded GLP-1 revenue pool deepening. CPA math ($260–$500 vs $8–40) structural.